Targeting STAT3 in gastric cancer

Andrew S Giraud1, Trevelyan R Menheniott, Louise M Judd

  • 1Murdoch Childrens Research Institute, Royal Childrens Hospital, Parkville, Australia. andrew.giraud@mcri.edu.au

Abstract

Insights

Signal transducer and activator of transcription 3 (STAT3) activation drives gastric cancer. Targeting STAT3 or its upstream regulators may prevent stomach cancer development and progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gastroenterology

Background:

  • Signal transducer and activator of transcription 3 (STAT3) is a crucial transcription factor regulating gene expression.
  • Dysregulated STAT3 activation is implicated in inflammation and cellular transformation, particularly in epithelial cancers.
  • STAT3 plays a significant role in the initiation and progression of gastric cancer.

Purpose of the Study:

  • To review the role of STAT3 in gastric cancer initiation and progression.
  • To emphasize STAT3 activation by cytokines in gastric cancer.
  • To discuss therapeutic strategies targeting STAT3 and its upstream drivers.

Main Methods:

  • Review of STAT3 signaling mechanics in gastric tumorigenesis.
  • Analysis of upstream regulators of STAT3, including Helicobacter pylori infection.
  • Examination of STAT3-activated genes promoting transformation and progression.
  • Discussion of STAT3 and cytokine inhibitors as therapeutics.

Main Results:

  • Constitutive STAT3 activation promotes gastric tumor development in human and mouse models.
  • Upstream regulators, including cytokines and H. pylori, contribute to STAT3 activation.
  • STAT3-activated genes are critical for cancer transformation and progression.

Conclusions:

  • Chronic STAT3 activation is a key event in gastric cancer induction and progression.
  • Targeting gastric epithelial STAT3 or specific signaling pathways (IL-11Rα/gp130, EGFR) may prevent gastric carcinogenesis.
  • Therapeutic inhibition of STAT3 signaling offers a promising strategy for gastric cancer prevention.